Vaccine News

Johnson & Johnson vaccine, the 3rd Vaccine to receive emergency use authorization in the fight against COVID-19 infection:

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third COVID-19 Vaccine, which is now available to fight COVID-19 infection. The Johnson & Johnson vaccine is a single-dose vaccine that is recommended for use in individuals age 18 and older. This Vaccine uses a type of virus known as the adenovirus to carry a piece of COVID-19 virus’s genetic material into the body to make a special protein found on the SARS-COV-2 virus. The virus is altered to prevent it from replicating itself in the body and causing illness. 

Once the Vaccine is given, the body starts to make the protein that triggers the immune system to build a defense against the virus.

The FDA has determined this Vaccine meets safety and effectiveness requirements to be used on an emergency basis to fight against the COVID-19 virus. The clinical trials results show that at least 14 days after receiving the Johnson and Johnson COVID-19 vaccine, the Vaccine was 77% effective in preventing severe symptoms from COVID-19 infection. The results also showed that at least 28 days after the vaccination, the Vaccine was about 85% effective in preventing several life-threatening illnesses from COVID-19.

For more information, please go to: